InMed Pharmaceuticals Inc(INM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:58 PM ET (Korea 9/12 06:58)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.12 | Insider Own | 25.81% | Shs Outstand | 5.3M | Perf Week | -3.01% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.5M | Perf Month | -10.42% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 56.37% | Short Float | 1.25% | Perf Quarter | -18.35% |
| Income | -0.01B | P/S | 3.65 | EPS this Y | - | Inst Trans | -7.82% | Short Ratio | 0.03 | Perf Half Y | 61.25% |
| Sales | 0.00B | P/B | 6.41 | EPS next 5Y | - | ROA | -122.41% | Short Interest | 0.03M | Perf YTD | 21.7% |
| Book/sh | 0.2 | P/C | 3.18 | EPS past 3/5Y | 63.64% 66.67% | ROE | -157% | 52W High | -48.4% ($2.50) | Perf Year | -40.28% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1168.44% | 52W Low | 124.35% ($0.57) | Perf 3Y | -93.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.05% | Gross Margin | -6.3% | Volatility(W/M) | 5.14% 6.72% | Perf 5Y | -99.88% |
| Dividend TTM | - | EV/Sales | 2.51 | Sales Y/Y TTM | -60.74% | Oper. Margin | -510.84% | ATR (14) | 0.09 | Perf 10Y | -99.89% |
| Dividend Ex-Date | - | Quick Ratio | 1.37 | EPS Q/Q | -60.54% | Profit Margin | -669.61% | RSI (14) | 37.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.37 | Sales Q/Q | -100% | SMA20 | -8.12% ($1.4) | Beta | 0.93 | Target Price | $468.78 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/9 | SMA50 | -13.91% ($1.5) | Rel Volume | 0.02 | Prev Close | $1.31 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 9.44% ($1.18) | Avg Volume(3M) | 0.92M | Price | $1.29 |
| IPO | 2008/11/17 | Option/Short | No/Yes | Trades | 210 | Volume | 22,493 | Change | -1.53% |
Company
INM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 A clinical-stage pharmaceutical company developing treatments for Alzheimer's disease and dry eye conditions, targeting CB1/CB2 receptors.
Over the past 1 year, roughly in the middle
48% below its 1-year high.
INM has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -93.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 56.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
XLC 22.6B
IGV 13.3B
PEJ 361M
GOLS 34M
ODDS 4MIt ranks #4 in the industry
Based on market cap of $7M.
INM $7M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is INM?
INM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of INM?
The market cap of INM is approximately $7M, ranking 5,601 within its sector.
What is the 52-week high and low for INM?
INM has recorded a 52-week high of $2.50 and a low of $0.57.
